AI Stock Analysis - Zymeworks (ZYME)
Analysis generated January 9, 2026.
Zymeworks Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative multi-functional therapeutics. The company uses its proprietary platforms to develop protein therapeutics and has a robust pipeline focused on oncology, with additional efforts in other therapeutic areas. Zymeworks aims to bring new therapies to market, which could potentially translate into significant growth if the therapies are successful.
Stock Alerts - Zymeworks (ZYME)
 |
Zymeworks | March 12 Price is down by -6.2% in the last 24h. |
|
Zymeworks | March 10 Price is up by 6.6% in the last 24h. |
|
Zymeworks | March 5 AI Score is up by 31.7% in the last couple of days. |
|
Zymeworks | March 3 Price is up by 6.2% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Zymeworks
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 6 | Sign up | Sign up | Sign up |
| Sentiment | 91 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 18 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,593 | Sign up | Sign up | Sign up |
| X Followers | 1,365 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 51 | Sign up | Sign up | Sign up |
| Linkedin Employees | 291 | Sign up | Sign up | Sign up |
About Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
| Price | $23.23 |
| Target Price | Sign up |
| Volume | 963,811 |
| Market Cap | $1.89B |
| Year Range | $12.02 - $27.62 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
Zymeworks Q4 Earnings Call HighlightsMarch 2 - Yahoo Entertainment |
|
Zymeworks Inc. Q4 2025 Earnings Call SummaryMarch 2 - Yahoo Entertainment |
|
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note FinancingMarch 2 - GlobeNewswire |
|
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 2 - Financial Post |
|
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note FinancingMarch 2 - Financial Post |
|
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a YearFebruary 22 - Yahoo Entertainment |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 28M | 0 | 28M | -20M | -16M | -0.260 |
| Q2 '25 | 49M | 3.2M | 49M | 2.3M | 2.6M | 0.030 |
| Q1 '25 | 27M | 3.3M | 27M | -23M | -22M | -0.300 |
| Q4 '24 | 31M | -27M | 31M | -24M | -19M | -0.310 |
| Q3 '24 | 16M | 2.7M | 16M | -30M | -32M | -0.390 |
Insider Transactions View All
| Moore Paul Andrew filed to sell 48,497 shares at $22.7. January 12 '26 |
| Smith Jeffrey T L filed to sell 26,708 shares at $22.7. January 12 '26 |
| Hollywood Mark filed to sell 132,913 shares at $22.7. January 13 '26 |
| Galbraith Kenneth filed to sell 226,842 shares at $22.7. January 12 '26 |
| Moore Paul Andrew filed to sell 31,212 shares at $25.1. January 5 '26 |
Similar companies
Read more about Zymeworks (ZYME) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Zymeworks
The Market Cap of Zymeworks is $1.89B.
Currently, the price of one share of Zymeworks stock is $23.23.
The ZYME stock price chart above provides a comprehensive visual representation of Zymeworks' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Zymeworks shares. Our platform offers an up-to-date ZYME stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Zymeworks (ZYME) does not offer dividends to its shareholders. Investors interested in Zymeworks should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Zymeworks are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
